Spruce Street Capital LP Buys Shares of 175,000 Lexeo Therapeutics, Inc. $LXEO

Spruce Street Capital LP bought a new stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) in the 4th quarter, Holdings Channel reports. The institutional investor bought 175,000 shares of the company’s stock, valued at approximately $1,738,000. Lexeo Therapeutics accounts for about 0.6% of Spruce Street Capital LP’s holdings, making the stock its 25th largest holding.

Several other large investors have also recently bought and sold shares of the company. Balyasny Asset Management L.P. bought a new position in Lexeo Therapeutics in the second quarter valued at about $16,117,000. Citadel Advisors LLC raised its position in Lexeo Therapeutics by 3.1% in the third quarter. Citadel Advisors LLC now owns 3,719,043 shares of the company’s stock valued at $24,694,000 after purchasing an additional 111,076 shares during the last quarter. Vestal Point Capital LP raised its position in Lexeo Therapeutics by 0.7% in the third quarter. Vestal Point Capital LP now owns 3,250,000 shares of the company’s stock valued at $21,580,000 after purchasing an additional 21,839 shares during the last quarter. State Street Corp raised its position in Lexeo Therapeutics by 485.1% in the fourth quarter. State Street Corp now owns 3,187,722 shares of the company’s stock valued at $31,654,000 after purchasing an additional 2,642,877 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Lexeo Therapeutics by 11.2% in the third quarter. Vanguard Group Inc. now owns 2,226,290 shares of the company’s stock valued at $14,783,000 after purchasing an additional 223,424 shares during the last quarter. 60.67% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Richard Nolan Townsend sold 55,000 shares of the firm’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $5.69, for a total transaction of $312,950.00. Following the completion of the transaction, the chief executive officer directly owned 340,106 shares in the company, valued at $1,935,203.14. This trade represents a 13.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 59,644 shares of company stock worth $336,462 in the last ninety days. 2.00% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have commented on the company. Chardan Capital reiterated a “buy” rating and issued a $17.00 target price on shares of Lexeo Therapeutics in a research report on Monday, May 11th. Weiss Ratings upgraded Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. Finally, Wall Street Zen upgraded Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Lexeo Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $20.14.

Lexeo Therapeutics Price Performance

Shares of LXEO opened at $4.65 on Tuesday. Lexeo Therapeutics, Inc. has a 1 year low of $3.60 and a 1 year high of $10.99. The company has a market capitalization of $365.12 million, a price-to-earnings ratio of -3.21 and a beta of 1.39. The business has a 50-day moving average of $5.50 and a 200-day moving average of $7.01.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. As a group, sell-side analysts anticipate that Lexeo Therapeutics, Inc. will post -1.23 EPS for the current year.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.